Clinical analysis of 14 cases of breast cancer therapy-related acute myeloid leukemia

Purpose: This study aims to summarize the clinical characteristics, treatment, and prognosis of breast cancer therapy-related acute myeloid leukemia (t-AML). Materials and Methods: Fourteen breast cancer patients with t-AML were enrolled, and their clinical characteristics, laboratory test results, treatment, and outcomes were retrospectively analyzed. Nine patients underwent bone marrow chromosome examination, of which five had balanced chromosomal translocations. Moreover, nine patients underwent fusion gene testing, and all nine cases were positive. Results: Three out of four patients with the M3 French–American–British subtype were in complete remission induced by treatment with tretinoin and daunorubicin; the fourth case stopped the chemotherapy. The remission rate of eight non-M3 patients with t-AML, who all received chemotherapy, was 50%. Breast cancer patients with t-AML were common in this study and had abnormal cytogenetics and molecular biology. Conclusions: Moreover, M3 breast cancer patients with t-AML achieved complete remission after chemotherapy, but non-M3 patients had a low remission rate.

Therapy-related; Acute leukemia; Breast cancer.

[1] Leone G., Fianchi L., Pagano L., Voso M.T.: “Incidence and susceptibility to therapy-related myeloid neoplasms”. Chem. Biol. Interact., 2010, 184, 39.

[2] Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al.: “The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes”. Blood, 2009, 114, 937.

[3] Vega-Stromberg T.: “Chemotherapy-induced secondary malignancies”. J. Infus. Nurs., 2003, 26, 353.

[4] Yang X., Hu Z., Wu J., Liu G., Di G., Chen C., et al.: “Germline mutations of TP53 gene among Chinese families with high risk for breast cancer”. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2015, 32, 761.

[5] Valentini C.G., Fianchi L., Voso M.T., Caira M., Leone G., Pagano L.: “Incidence of acute myeloid leukemia after breast cancer”. Mediterr. J. Hematol. Infect. Dis., 2011, 3, e2011069.

[6] Praga C., Bergh J., Bliss J., Bonneterre J., Cesana B., Coombes R.C., et al.: “Risk of acute myeloid leukemia and myelodysplastic syndromes in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide”. J. Clin. Oncol., 2005, 23, 4179.

[7] Mauritzson N., Albin M., Rylander L., Billström R., Ahlgren T., Mikoczy Z., et al.: “Pooled analysis of clinical and cytogenetic features in treatment-related and denovo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001”. Leukemia, 2002, 16, 2366.

[8] Mufti G.J.: “Pathobiology, classification and diagnosis of myelodysplastic syndrome”. Best Pract. Res. Clin. Haematol., 2004, 17, 543.

[9] Smith R.E., Bryant J., DeCillis A., Anderson S., National Surgical Adjuvant Breast and Bowel Project Experience.: “Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience”. J. Clin. Oncol., 2003, 21, 1195.

[10] Shaffer L.G. (ed). An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: ISCN, 2009.

[11] Thirmann M.J., Larson R.A.: “Therapy-related myeloid leukemia”. Hematol. Oncol. Clin. North Am., 1996, 10, 293.

[12] Howard R.A., Gilbert E.S., Chen B.E., Hall P., Storm H., Pukkala E., et al.: “Leukemia following breast cancer: an international population-based study of 376, 825 women”. Breast Cancer Res. Treat., 2007, 105, 359.

[13] Aldoss I., Pullarkat V.: “Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable”? Leuk Res., 2012, 36, 1547.

[14] Takeyama K., Seto M., Uike N., Hamajima N., Ino T., Mikuni C., et al.: “Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical andcytogenetic features as well as prognostic factors”. Int. J. Hematol., 2000, 71, l44.

[15] Bally C., Thépot S., Quesnel B., Vey N., Dreyfus F., Fadlallah J., et al.: “Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM)”. Leuk Res., 2013, 37, 637.

[16] Spina F., Alessandrino P.E., Milani R., Bonifazi F., Bernardi M., Luksch R., et al.: “Allogeneic stem cell transplantation in therapyrelated acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant”. Leuk. Lymphoma., 2012, 53, 96.

[17] Armand P., Kim H.T., Mayer E., Cutler C.S., Ho V.T., Koreth J., et al.: “Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy”. Bone Marrow Transplant., 2010, 45, 1611.

[18] Rowley J.D., Olney H.J.: “International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report”. Genes Chromosomes Cancer, 2002, 33, 331.

[19] Slovak M.L., Bedell V., Popplewell L., Arber D.A., Schoch C., Slater R.: “21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop”. Genes Chromosomes Cancer, 2002, 33, 379.

[20] Park H.J., Choi J.H., Lee K.A., Kim H.C., Nam Y.S., Oh Y.H., et al.: “A case of therapy-related acute myeloid leukemia following 5- fluorouracil chemotherapy”. Korean J. Intern. Med., 2012, 27, 115.

[21] Utsu Y., Aotsuka N., Masuda S., Matsuura Y., Wakita H.: “Atypical onset of therapy-related acute promyelocytic leukemia after combined modality therapy including (89)Sr for metastatic breast cancer”. Rinsho. Ketsueki., 2013, 54, 759.

[22] Kaplan H.G., Malmgren J.A., Atwood M.K.: “Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005”. BMC Cancer, 2011, 11, 260.

[23] Nardi V., Winkfield K.M., Ok C.Y., Niemierko A., Kluk M.J., Attar E.C., et al.: “Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novodisease and differ from other therapy-related myeloid neoplasms”. J. Clin. Oncol., 2012, 30, 2340.

[24] Chen Y., Estrov Z., Pierce S., Qiao W., Borthakur G., Ravandi F., et al.: “Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor”. Leuk Lymphoma., 2015, 56, 1012.

[25] Cui W., Zhang D., Cunningham M.T., Tilzer L.: “Leukemia-associated aberrant immunophenotype in patients with acute myeloid leukemia: changes at refractory disease or first relapse and clinicopathological findings”. Int. J. Lab. Hematol., 2014, 36, 636.